Yes, upon request.

Infectious disease screening for HIV, HBV, and HCV is performed on a sample of the cord blood.

Yes, upon request.

Yes, a donor is eligible to donate bone marrow every 16 weeks and other blood products after 4 weeks.

Yes, this data is available upon request.

It takes 2 weeks on average. Schedule your delivery today to ensure the quickest turn around time.

Yes, we can customize the collection based on specific requests.

Yes, depending on the cell types.

We can collect up to 250 ml into tubes.

We can collect whole peripheral blood in a variety of anticoagulants, such as EDTA, ACD-A, heparin or any anticoagulant of your choosing.

Yes, a donor is eligible to donate white blood cells every 4 weeks.

Usually around 8×10⁹ PBMCs from a Fresh Leukopak. However, this will be dependent on how you process the Leukopak (Ficoll, RBC lysis, etc.), all of which can decrease the amount of PBMCs.

No, we offer a high-quality Leukopak with minimal granulocytes and red blood cells. However, we do recommend an RBC lysis before isolating primary cells.

Cells are very sensitive to many aspects of the thawing procedure, such as heat, DMSO, agitation, and high centripetal forces. Obtaining high cell viability and recovery after thawing a Frozen Leukopak can be difficult if not performed quickly and with good laboratory techniques. At StemExpress, our laboratory technicians have years of experience handling and thawing frozen human cells and have designed a procedure that will help you obtain the highest viability and recovery of your cells. Click Leukopak Thawing Protocol to access the protocol.

Yes, depending on the cell types

Primary cells are very sensitive to many aspects of the thawing procedure, such as heat, DMSO, agitation, and high centripetal forces. Obtaining high viability after thawing human primary cells can be difficult if not performed quickly and with good laboratory techniques. At StemExpress, our laboratory technicians have years of experience handling and thawing frozen human primary cells and have designed a procedure that will help you obtain the highest viability of your cells.

Under aseptic conditions in Class II, laminar-flow hoods.

We offer G-CSF, Plerixafor, and G-CSF plus Plerixafor options to mobilize the cells from the bone marrow.

Yes, LCMV testing can be done upon request.

StemExpress offers PBMCs and CD34+ stem cells mobilized with G-CSF, Plerixafor, and G-CSF plus plerixafor. The mechanism of action of these mobilization agents, and the combination of them, have been shown to change the expression profile, cell composition, and engraftment potential of the mobilized cells.^1,2,3 Therefore, it is important to understand that switching mobilization reagents during a study may also change the mobilized cell type and their effect on studies relating to transplantation and stem cell research.

1. Broxmeyer, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201(8):1307–1318.
2. Larochelle, et al. (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 107(9):3772–3778.
3. Lidonnici, et al. (2017) Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. Haematol. 102(4):120-124.

• Procures healthy and diseased human tissue and blood
• Isolates cells
• Processes whole blood (umbilical cord, adult peripheral, and maternal)
• Cultures selected cell types
• Isolates DNA and RNA
• Conducts immunophenotyping using flow cytometry

We offer G-CSF, Plerixafor, and G-CSF plus Plerixafor options to mobilize the cells from the bone marrow.

StemExpress offers PBMCs and CD34+ stem cells mobilized with G-CSF, Plerixafor, and G-CSF plus plerixafor. The mechanism of action of these mobilization agents, and the combination of them, have been shown to change the expression profile, cell composition, and engraftment potential of the mobilized cells.^1,2,3 Therefore, it is important to understand that switching mobilization reagents during a study may also change the mobilized cell type and their effect on studies relating to transplantation and stem cell research.

1. Broxmeyer, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201(8):1307–1318.
2. Larochelle, et al. (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 107(9):3772–3778.
3. Lidonnici, et al. (2017) Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. Haematol. 102(4):120-124.

Primary cells are very sensitive to many aspects of the thawing procedure, such as heat, DMSO, agitation, and high centripetal forces. Obtaining high viability after thawing human primary cells can be difficult if not performed quickly and with good laboratory techniques. At StemExpress, our laboratory technicians have years of experience handling and thawing frozen human primary cells and have designed a procedure that will help you obtain the highest viability of your cells.

Yes. StemExpress is happy to work with researchers to meet the specific needs of their work.

We offer G-CSF, Plerixafor, and G-CSF plus Plerixafor options to mobilize the cells from the bone marrow.

Yes, LCMV testing can be done upon request.

StemExpress offers PBMCs and CD34+ stem cells mobilized with G-CSF, Plerixafor, and G-CSF plus plerixafor. The mechanism of action of these mobilization agents, and the combination of them, have been shown to change the expression profile, cell composition, and engraftment potential of the mobilized cells.^1,2,3 Therefore, it is important to understand that switching mobilization reagents during a study may also change the mobilized cell type and their effect on studies relating to transplantation and stem cell research.

1. Broxmeyer, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 201(8):1307–1318.
2. Larochelle, et al. (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 107(9):3772–3778.
3. Lidonnici, et al. (2017) Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. Haematol. 102(4):120-124.

Our cord blood is collected into sterile bags containing the anticoagulant CP2D. However, you can request to have a different anticoagulant used for collection.

Each cord is different and the number of CD 34+ cells varies greatly among the individual donors. Typically, 1-4 million CD 34+ cells per cord can be collected. We can provide larger lots upon request

Yes, upon request.

Yes, we have many researchers that use our CD34+ cells to humanize mice.

Infectious disease screening for HIV, HBV, and HCV is performed on a sample of the cord blood.

Yes, upon request